Archives

  • 2022-05
  • 2022-04
  • 2021-03
  • 2020-08
  • 2020-07
  • 2020-03
  • 2019-11
  • 2019-10
  • 2019-09
  • 2019-08
  • 2019-07
  • br Carenza E Barcel V

    2022-05-06


    48. Carenza E, Barceló V, Morancho A, Levander L, Boada C, Laromaine A, et al. In vitro angiogenic performance and in vivo brain targeting of magnetized endothelial progenitor cells for neurorepair therapies. Na-nomedicine: NBM 2014;10(1):225-34.
    49. Matuszak J, Zaloga J, Friedrich RP, Lyer S, Nowak J, Odenbach S, et al. Endothelial biocompatibility and accumulation of SPION under flow conditions. J Magn Magn Mater 2015;380:20-6.
    50. Sundstrøm T, Daphu I, Wendelbo I, Hodneland E, Lundervold A, Immervoll H, et al. Automated tracking of nanoparticle-labeled melanoma cells improves the predictive power of a T-5224 metastasis model. Cancer Res 2013;73:2445-56.
    51. Lu X, Liu W, Ouyang J, Tian Y. Distinct surface hydration behaviours of boron-rich boride thin film coatings. Appl Surf Sci 2014;311:749-52. 52. M Wang Y-XJ. Superparamagnetic iron oxide based MRI contrast agents: current status of clinical application. Quant Imaging Med Surg 2011;1:35-40.
    53. Geninatti-Crich S, Alberti D, Szabo I, Deagostino A, Toppino A, Barge A, et al. MRI-guided neutron capture therapy by use of a dual gadolinium/boron agent targeted at tumour cells through upregulated low-density lipoprotein transporters. Chemistry 2011;17(30):8479-86.
    54. Deagostino A, Protti N, Alberti D, Boggio P, Bortolussi S, Altieri S, et al. Insights into the use of gadolinium and gadolinium/boron-based agents in imaging-guided neutron capture therapy applications. Future Med Chem 2016;8(8):899-917.
    56. Salvati A, Pitek AS, Monopoli MP, Prapainop K, Bombelli FB, Hristov DR, et al. Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. Nat Nanotechnol 2013;8(2):137-43.
    57. Angelopoulos I, Southern P, Pankhurst QA, Day RM. Superparamag-netic iron oxide nanoparticles regulate smooth muscle cell phenotype. J Biomed Mater Res A 2016;104:2412-9.
    58. Wilhelm C, Gazeau F. Universal cell labelling with anionic magnetic nanoparticles. Biomaterials 2008;29:3161-74.
    59. Barth RF, Vicente GMH, Harling OK, Kiger III WS, Riley KJ, Binns PJ, et al. Current status of boron neutron capture therapy of high grade gliomas and recurrent head and neck cancer. Radiat Oncol 2012;7:146-67. 
    Laboratory-Prostate cancer
    Combining urinary DNA methylation and cell-free microRNA biomarkers for improved monitoring of prostate cancer patients on active surveillance
    a Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Ontario, Canada b Laboratory Medicine & Pathobiology, University of Toronto, Toronto, Ontario, Canada c Odette Cancer Research Program, Sunnybrook Research Institute, Toronto, Ontario, Canada
    Abstract
    Purpose: Prostate cancer (CaP) patients with low-grade tumors are enrolled in active surveillance (AS) programs and monitored with digital rectal exams (DREs), prostate-specific antigen (PSA) tests, and periodic invasive biopsies. Patients are “reclassified” with higher-risk disease if they show signs of disease progression. However, AS patients who will reclassify cannot be easily identified upfront and suf-fer morbidities associated with biopsy. Biomarkers derived from noninvasively obtained specimens such as serum or urine samples are promising alternatives to monitor patients with clinically insignificant cancer. Previously, we have characterized and validated a urinary DNA methylation panel and a serum miRNA panel for the prediction of patient reclassification in 2 independent AS cohorts. In this explor-atory study, we have investigated cell-free miRNAs in the urinary supernatant combined with urinary DNA methylation markers to form an integrative panel for prediction of AS patient reclassification.
    Methods: Post-DRE urine was collected from 103 CaP patients on active surveillance. Urinary sediment DNA methylation levels of selected genes were previously analyzed using qPCR-based MethyLight assay. Using qRT-PCR, we analyzed the urinary supernatants for relative quantities of 10 miRNAs previously shown to be associated with AS reclassification. Logistic regression and Receiver Operating Characteristics curve analyses were performed to assess the predictive ability of miRNAs and DNA methylation biomarkers.
    Results: We identified a 3-marker panel, consisting of miR-24, miR-30c and CRIP3 methylation, that was significant for prediction of patient reclassification (Odds ratio = 2.166, 95% confidence interval = 1.22−3.847) with a negative predictive value of 90.9%. Our 3-marker panel also demonstrated additive value to PSA for prediction of patient reclassification (c-statistic = 0.717, ROC bootstrapped 1000 iteration P = 0.041).
    Conclusion: A urinary integrated panel of methylation and miRNA markers is a promising approach to identify AS patients at risk for reclassification. Our 3-marker panel, with its high negative predictive value, would be beneficial to identify and preclude AS patients with truly indolent cancer and to personalize monitoring strategies for AS patients. 2019 Elsevier Inc. All rights reserved.